The present invention relates generally to caps for providing antimicrobial protection to an IV access port or other type of device having a female luer connection. In particular, the caps of the present invention can be used to distribute an antimicrobial solution within the intraluminal space of a female luer device.
Currently, there are various products available for capping a port of an intravenous device (e.g. a catheter or other infusion device). In this specification, port will be used generally to describe any type of connector for interconnecting two devices. For example,
In this specification, a female luer connector should be interpreted as any connector having an internal lumen that is tapered to conform to a corresponding male connector having the same or similar degree of tapering. These female luer connectors can include luer lock and luer slip (or non-lock luer) connectors.
Intravenous devices can employ ports to provide quick access to a patient's vasculature. These ports also enable the device to remain within the patient's vasculature even when no access to the vasculature is needed. When a port of an intravenous device is not in use, it is desirable to maintain the port clean and free from bacteria and other microbes. If the port becomes contaminated with microbes while not in use, it is possible that the microbes will be flushed into the patient's vasculature once the port is again used for accessing the patient's vasculature. Accordingly, maintaining a sterile port is essential to minimize the risk of infection.
To maintain the sterility of a port, various types of caps have been designed. These caps typically contain an antimicrobial solution that is applied to the exterior surfaces of the port when a cap is attached to the port. For example, some caps employ an alcohol-soaked material that is disposed within the cavity of the cap so that the material scrubs the exterior surfaces of the port when the cap is screwed on. Once screwed on, these caps can retain an amount of the antimicrobial solution around the exterior surface of the port to ensure that the exterior surface remains sterile until the cap is removed.
These caps have proven to be effective for disinfecting the exterior surfaces of the port. However, current designs only disinfect the exterior surfaces. Any microbes that may exist within the intraluminal space will likely remain even after these current caps are used.
Alternatively, to address this risk of infection, some ports are configured to have antimicrobial coatings on the intraluminal surfaces. With such coatings, the intraluminal surfaces can remain sterile even if microbes come in contact with the surfaces. These coatings can also dissolve into the fluid within the lumen to effectively spread antimicrobial agents throughout the lumen. However, there are various drawbacks to using antimicrobial coatings on the intraluminal surfaces of ports. For example, ports that employ antimicrobial coatings are significantly more expensive to produce. As a result many facilities choose not to use them. Also, for a coating to be effective, it must retain its antimicrobial properties for at least the amount of time that the port could possibly be used (e.g. up to 7 days). To accomplish this, relatively thick coatings or highly concentrated coatings are used. This causes the concentration of antimicrobial agents to be very high during the initial usage time which poses a toxicity risk.
The present invention extends to caps for providing antimicrobial protection to a female luer port of an intravenous device. The caps of the present invention are designed to distribute an antimicrobial solution within the intraluminal surfaces of the port. Additionally, in some embodiments, the caps are designed to also distribute an antimicrobial solution around the exterior surfaces of the port. Accordingly, the caps of the present invention provide a complete solution for disinfecting a port of an intravenous device.
In one embodiment, the present invention is implemented as a cap for a port of an intravenous device. The cap can comprise a body having a cavity; an actuator positioned within the cavity; and an absorbent material containing an antimicrobial solution. The absorbent material is contained within the cavity between the actuator and an inner surface of the body. When the cap is connected to a port of an intravenous device, the actuator is forced into the cavity and compresses the absorbent material causing the antimicrobial solution to flow onto an intraluminal surface of the port.
In some embodiments, the actuator comprises a lumen through which the antimicrobial solution flows to reach a lumen of the port.
In some embodiments, the actuator comprises a male luer in which the lumen is formed.
In some embodiments, the antimicrobial solution flows through a gap between the body and an exterior surface of the actuator and onto an exterior surface of the port.
In some embodiments, the body includes a seal that the actuator contacts when the cap is connected to the port thereby forming a seal between the actuator and the body.
In some embodiments, the concentration of an antimicrobial agent within the antimicrobial solution is selected such that when the antimicrobial solution mixes with fluid contained within the lumen of the port, the concentration of the antimicrobial agent remains higher than the minimum inhibitory concentration of the antimicrobial agent.
In some embodiments, the port is a female luer into which the actuator inserts.
In some embodiments, the port is a needleless connector into which the actuator inserts.
In some embodiments, the actuator includes a protrusion that is positioned within a lumen in the body, the protrusion having a lumen through which the antimicrobial solution flows.
In some embodiments, the actuator includes a plurality of prongs that extend through corresponding openings in the body.
In some embodiments, the antimicrobial solution flows through the openings when the actuator is forced into the cavity.
In some embodiments, the actuator includes a lumen that has an antimicrobial coating.
In another embodiment, the present invention is implemented as a cap for a port of an intravenous device. The cap can comprise a body having a cavity; an actuator positioned within the cavity, the actuator having a lumen; and an absorbent material containing an antimicrobial solution, the absorbent material being contained within the cavity between the actuator and an inner surface of the body. Prior to the cap being connected to a port of an intravenous device, the absorbent material remains uncompressed. Then, when the cap is connected to a port of an intravenous device, the actuator compresses the absorbent material causing the antimicrobial solution to flow through the lumen of the actuator and into a lumen of the port.
In some embodiments, the actuator is sized such that a gap exists between an outer edge of the actuator and a wall of the cavity, the antimicrobial solution also flowing through the gap onto an exterior surface of the port.
In some embodiments, the actuator includes a plurality of prongs which extend through corresponding openings in the body. The antimicrobial solution flows through the openings onto the exterior surface of the port
In some embodiments, the body includes a seal for sealing the lumen of the actuator.
In some embodiments, the actuator comprises a male luer.
In another embodiment, the present invention is implemented as a cap for a needleless connector of an intravenous device. The cap can comprise a body having a cavity; an absorbent material positioned within the cavity, the absorbent material containing an antimicrobial solution; and an actuator positioned within the cavity against the absorbent material. The actuator is moveable within the cavity to compress the absorbent material such that upon the cap being connected to a needleless connector, the needleless connector causes the actuator to compress the absorbent material releasing the antimicrobial solution onto an intraluminal surface of the needleless connector.
In some embodiments, the actuator comprises a lumen. The antimicrobial solution flows through the lumen of the actuator onto the intraluminal surface of the needleless connector.
In some embodiments, the antimicrobial solution also flows around an exterior surface of the actuator onto an exterior surface of the needleless connector.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key features or essential features of the claimed subject matter.
Additional features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by the practice of the invention. The features and advantages of the invention may be realized and obtained by means of the instruments and combinations particularly pointed out in the appended claims. These and other features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
In order to describe the manner in which the above-recited and other advantages and features of the invention can be obtained, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. Understanding that these drawings depict only typical embodiments of the invention and are not therefore to be considered to be limiting of its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
The present invention extends to caps for providing antimicrobial protection to a female luer port of an intravenous device. The caps of the present invention are designed to distribute an antimicrobial solution within the intraluminal surfaces of the port. Additionally, in some embodiments, the caps are designed to also distribute an antimicrobial solution around the exterior surfaces of the port. Accordingly, the caps of the present invention provide a complete solution for disinfecting a port of an intravenous device.
In one embodiment, the present invention is implemented as a cap for a port of an intravenous device. The cap can comprise a body having a cavity; an actuator positioned within the cavity; and an absorbent material containing an antimicrobial solution. The absorbent material is contained within the cavity between the actuator and an inner surface of the body. When the cap is connected to a port of an intravenous device, the actuator is forced into the cavity and compresses the absorbent material causing the antimicrobial solution to flow onto an intraluminal surface of the port.
In some embodiments, the actuator comprises a lumen through which the antimicrobial solution flows to reach a lumen of the port.
In some embodiments, the actuator comprises a male luer in which the lumen is formed.
In some embodiments, the antimicrobial solution flows through a gap between the body and an exterior surface of the actuator and onto an exterior surface of the port.
In some embodiments, the body includes a seal that the actuator contacts when the cap is connected to the port thereby forming a seal between the actuator and the body.
In some embodiments, the concentration of an antimicrobial agent within the antimicrobial solution is selected such that when the antimicrobial solution mixes with fluid contained within the lumen of the port, the concentration of the antimicrobial agent remains higher than the minimum inhibitory concentration of the antimicrobial agent.
In some embodiments, the port is a female luer into which the actuator inserts.
In some embodiments, the port is a needleless connector into which the actuator inserts.
In some embodiments, the actuator includes a protrusion that is positioned within a lumen in the body, the protrusion having a lumen through which the antimicrobial solution flows.
In some embodiments, the actuator includes a plurality of prongs that extend through corresponding openings in the body.
In some embodiments, the antimicrobial solution flows through the openings when the actuator is forced into the cavity.
In some embodiments, the actuator includes a lumen that has an antimicrobial coating.
In another embodiment, the present invention is implemented as a cap for a port of an intravenous device. The cap can comprise a body having a cavity; an actuator positioned within the cavity, the actuator having a lumen; and an absorbent material containing an antimicrobial solution, the absorbent material being contained within the cavity between the actuator and an inner surface of the body. Prior to the cap being connected to a port of an intravenous device, the absorbent material remains uncompressed. Then, when the cap is connected to a port of an intravenous device, the actuator compresses the absorbent material causing the antimicrobial solution to flow through the lumen of the actuator and into a lumen of the port.
In some embodiments, the actuator is sized such that a gap exists between an outer edge of the actuator and a wall of the cavity, the antimicrobial solution also flowing through the gap onto an exterior surface of the port.
In some embodiments, the actuator includes a plurality of prongs which extend through corresponding openings in the body. The antimicrobial solution flows through the openings onto the exterior surface of the port
In some embodiments, the body includes a seal for sealing the lumen of the actuator.
In some embodiments, the actuator comprises a male luer.
In another embodiment, the present invention is implemented as a cap for a needleless connector of an intravenous device. The cap can comprise a body having a cavity; an absorbent material positioned within the cavity, the absorbent material containing an antimicrobial solution; and an actuator positioned within the cavity against the absorbent material. The actuator is moveable within the cavity to compress the absorbent material such that upon the cap being connected to a needleless connector, the needleless connector causes the actuator to compress the absorbent material releasing the antimicrobial solution onto an intraluminal surface of the needleless connector.
In some embodiments, the actuator comprises a lumen. The antimicrobial solution flows through the lumen of the actuator onto the intraluminal surface of the needleless connector.
In some embodiments, the antimicrobial solution also flows around an exterior surface of the actuator onto an exterior surface of the needleless connector.
With continued reference to
As shown in
The primary pathway along which the antimicrobial solution flows is through lumen 320 of actuator 302. Because lumen 320 aligns with lumen 120 of port 100, the antimicrobial solution flowing through lumen 320 will ultimately be distributed along the surfaces of lumen 120 and into any fluid contained within lumen 120. In this way, the intraluminal surfaces of port 100 can be disinfected.
The secondary pathway is around actuator 302 as depicted by the outer arrows in
As shown in
Accordingly, the design of cap 300 allows the intraluminal surfaces of a port to be disinfected. Because the lumen of port 100 may typically contain a fluid (e.g. a saline solution or other solution that was infused into the patient), the antimicrobial solution can mix with the fluid to enhance the distribution of the antimicrobial agents throughout lumen 120.
When cap 300 is fully connected to port 100, a seal can be formed between actuator 302 and seal 304 as shown in
However, because of the positioning of openings 1051 near the edges of port 1100, the antimicrobial solution that flows through openings 1051 will more easily flow onto the exterior surfaces of port 1100. Additionally, as with cap 300, the primary pathway of the flow of the antimicrobial solution is through lumen 1020 and into lumen 1120 of port 1100.
Although
The caps of the present invention also provide the advantage of minimizing the concentrations of antimicrobial solution that must be used to ensure that the port is adequately disinfected. For example, as stated in the Background, one problem that arises when antimicrobial coatings are used is that the coatings may be too concentrated and may therefore pose toxicity problems. In contrast, because the caps of the present invention are intended for one-time use and are deployed when the port is not in use, the concentrations of antimicrobial solution can be minimized. In other words, in contrast to coatings which must remain active from the time they are applied to the port (e.g. when manufactured) until the port will no longer be used, the caps of the present invention will only remain on the port in between uses. Because the fluid volume in the port is static and fixed, the concentration of the antimicrobial solution will not change when the cap is in place. Therefore a reduced concentration of antimicrobial solution can be employed in the caps of the present invention while still providing adequate antimicrobial protection. In some embodiments, the concentration of the antimicrobial solution (or the concentration once mixed with fluid already present within the lumen of the port) can be just higher than the minimum inhibitory concentration of the antimicrobial agent in the solution.
Many different types of antimicrobial solutions may be used in caps of the present invention. For example, any antimicrobial agent that is soluable in alcohol, saline, or saline/heparin solutions can be employed. The concentration of the antimicrobial agent within the antimicrobial solution can be selected so that the resulting concentration of the agent once the antimicrobial solution is mixed with the fluid in the lumen of the port is above the minimum inhibitory concentration of the antimicrobial agent. Suitable antimicrobial agents include CHA and CHG among others.
In alternate embodiments, the lumen of the actuator can be coated with an antimicrobial coating. In such embodiments, the cap may or may not also include the absorbent material containing the antimicrobial solution. For example, when the cap does not include the absorbent material, the antimicrobial protection can be provided when the fluid within the lumen of the port contacts the antimicrobial coating within the lumen of the actuator. The dry antimicrobial coating can dissolve into the fluid to thereby disinfect the lumen of the port. Providing an antimicrobial coating on the lumen of the actuator as opposed to on the lumen of the port can allow a lower concentration of antimicrobial agent to be used for the reasons described above.
When the cap does include the absorbent material and an antimicrobial coating, the flow of the antimicrobial solution from the absorbent material may be partially or completely directed around the exterior of the actuator to ensure distribution on the exterior surfaces of the port. Some antimicrobial solution may be designed to flow through the lumen in the actuator to assist in distributing the antimicrobial coating throughout the lumen of the port. In this way, an antimicrobial solution can still be directed to both the intraluminal and the exterior surfaces of the port.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application is a continuation of U.S. application Ser. No. 15/674,389, filed Aug. 10, 2017, entitled IV ACCESS PORT CAP FOR PROVIDING ANTIMICROBIAL PROTECTION, which is a continuation of U.S. application Ser. No. 15/041,931, filed Feb. 11, 2016, entitled IV ACCESS PORT CAP FOR PROVIDING ANTIMICROBIAL PROTECTION, which is a continuation of U.S. application Ser. No. 14/185,827, filed Feb. 20, 2014, entitled IV ACCESS PORT CAP FOR PROVIDING ANTIMICROBIAL PROTECTION, which are incorporated herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2961682 | Wurmbock et al. | Nov 1960 | A |
4280632 | Yuhara | Jul 1981 | A |
4282891 | Duceppe | Aug 1981 | A |
4354490 | Rogers | Oct 1982 | A |
4417890 | Dennehey et al. | Nov 1983 | A |
4432764 | Lopez | Feb 1984 | A |
4440207 | Genatempo et al. | Apr 1984 | A |
4444310 | Odell | Apr 1984 | A |
4584192 | Dell et al. | Apr 1986 | A |
4624664 | Peluso et al. | Nov 1986 | A |
4626664 | Grise | Dec 1986 | A |
4655762 | Rogers | Apr 1987 | A |
4671306 | Spector | Jun 1987 | A |
4716032 | Wesffall et al. | Dec 1987 | A |
4753358 | Virca | Jun 1988 | A |
4778447 | Velde et al. | Oct 1988 | A |
4915934 | Tomlinson | Apr 1990 | A |
4925668 | Khan et al. | May 1990 | A |
4989733 | Patry | Feb 1991 | A |
4991629 | Ernesto et al. | Feb 1991 | A |
5023082 | Friedman et al. | Jun 1991 | A |
5195957 | Tollini | Mar 1993 | A |
5242425 | White et al. | Sep 1993 | A |
5334388 | Hoang et al. | Aug 1994 | A |
5335373 | Dangman et al. | Aug 1994 | A |
5512199 | Khan et al. | Apr 1996 | A |
5547662 | Khan et al. | Aug 1996 | A |
5554106 | Layman-Spillar et al. | Sep 1996 | A |
5554135 | Menyhay | Sep 1996 | A |
5569207 | Gisselberg et al. | Oct 1996 | A |
5616338 | Fox, Jr. et al. | Apr 1997 | A |
5620424 | Abramson | Apr 1997 | A |
5639310 | Giampaolo, Jr. | Jun 1997 | A |
5641464 | Briggs, III et al. | Jun 1997 | A |
5686096 | Khan et al. | Nov 1997 | A |
5694978 | Heilmann et al. | Dec 1997 | A |
5702017 | Goncalves | Dec 1997 | A |
5706944 | Hoang et al. | Jan 1998 | A |
5722537 | Sigler | Mar 1998 | A |
5743884 | Hasson et al. | Apr 1998 | A |
5792120 | Menyhay | Aug 1998 | A |
5817344 | Hoang et al. | Oct 1998 | A |
5861440 | Gohla et al. | Jan 1999 | A |
5954957 | Chin-Loy et al. | Sep 1999 | A |
5989229 | Chiappetta | Nov 1999 | A |
6045539 | Menyhay | Apr 2000 | A |
6051609 | Yu et al. | Apr 2000 | A |
6116468 | Nilson | Sep 2000 | A |
6117114 | Paradis | Sep 2000 | A |
6196998 | Jansen et al. | Mar 2001 | B1 |
6227391 | King | May 2001 | B1 |
6337357 | Fukunishi et al. | Jan 2002 | B1 |
6413539 | Shalaby | Jul 2002 | B1 |
6488942 | Ingemann | Dec 2002 | B1 |
6523686 | Bae | Feb 2003 | B1 |
RE38145 | Lynn | Jun 2003 | E |
6708363 | Larsen | Mar 2004 | B2 |
6846846 | Modak et al. | Jan 2005 | B2 |
6861060 | Luriya et al. | Mar 2005 | B1 |
6911025 | Miyahara | Jun 2005 | B2 |
6994315 | Ryan et al. | Feb 2006 | B2 |
7083605 | Miyahara | Aug 2006 | B2 |
7198611 | Connell et al. | Apr 2007 | B2 |
7198800 | Ko | Apr 2007 | B1 |
7268165 | Greten et al. | Sep 2007 | B2 |
7282186 | Lake, Jr. et al. | Oct 2007 | B2 |
7452349 | Miyahara | Nov 2008 | B2 |
7682561 | Davis et al. | Mar 2010 | B2 |
7704935 | Davis et al. | Apr 2010 | B1 |
7763006 | Tennican | Jul 2010 | B2 |
7828186 | Wales | Nov 2010 | B2 |
7922701 | Buchman | Apr 2011 | B2 |
8065773 | Vaillancourt et al. | Nov 2011 | B2 |
8113731 | Cable, Jr. et al. | Feb 2012 | B2 |
8162899 | Tennican | Apr 2012 | B2 |
8167847 | Anderson et al. | May 2012 | B2 |
8491546 | Hoang et al. | Jul 2013 | B2 |
8740864 | Hoang et al. | Jun 2014 | B2 |
9039989 | Liu et al. | May 2015 | B2 |
9283367 | Hoang et al. | Mar 2016 | B2 |
9283368 | Hoang et al. | Mar 2016 | B2 |
9283369 | Ma | Mar 2016 | B2 |
9399125 | Burkholz | Jul 2016 | B2 |
9480833 | Hoang et al. | Nov 2016 | B2 |
20010016589 | Modak et al. | Aug 2001 | A1 |
20020144705 | Brattesani et al. | Oct 2002 | A1 |
20020193752 | Lynn | Dec 2002 | A1 |
20030072781 | Pelerin | Apr 2003 | A1 |
20030109853 | Harding et al. | Jun 2003 | A1 |
20030153865 | Connell et al. | Aug 2003 | A1 |
20030162839 | Symington et al. | Aug 2003 | A1 |
20040004019 | Busch | Jan 2004 | A1 |
20040039349 | Modak et al. | Feb 2004 | A1 |
20040258560 | Lake, Jr. et al. | Dec 2004 | A1 |
20050124970 | Kunin et al. | Jun 2005 | A1 |
20050147524 | Bousquet | Jul 2005 | A1 |
20050147525 | Bousquet | Jul 2005 | A1 |
20050222542 | Burkholz et al. | Oct 2005 | A1 |
20060030827 | Raulerson et al. | Feb 2006 | A1 |
20060165751 | Chudzik et al. | Jul 2006 | A1 |
20060239954 | Sancho | Oct 2006 | A1 |
20070112333 | Hoang et al. | May 2007 | A1 |
20070202177 | Hoang | Aug 2007 | A1 |
20070225660 | Lynn | Sep 2007 | A1 |
20070282280 | Tennican | Dec 2007 | A1 |
20080019889 | Rogers et al. | Jan 2008 | A1 |
20080027399 | Harding et al. | Jan 2008 | A1 |
20080033371 | Updegraff et al. | Feb 2008 | A1 |
20080075761 | Modak et al. | Mar 2008 | A1 |
20080086091 | Anderson et al. | Apr 2008 | A1 |
20080095680 | Steffens et al. | Apr 2008 | A1 |
20080147047 | Davis et al. | Jun 2008 | A1 |
20080177250 | Howlett et al. | Jul 2008 | A1 |
20080182921 | Suh et al. | Jul 2008 | A1 |
20090008393 | Howlett et al. | Jan 2009 | A1 |
20090028750 | Ryan | Jan 2009 | A1 |
20090028756 | Shahriari | Jan 2009 | A1 |
20090062766 | Howlett et al. | Mar 2009 | A1 |
20090149818 | Timm | Jun 2009 | A1 |
20090149819 | Chelak | Jun 2009 | A1 |
20090175759 | Davis et al. | Jul 2009 | A1 |
20100000040 | Shaw et al. | Jan 2010 | A1 |
20100047123 | Solomon et al. | Feb 2010 | A1 |
20100049170 | Solomon et al. | Feb 2010 | A1 |
20100050351 | Colantonio et al. | Mar 2010 | A1 |
20100172794 | Ferlic et al. | Jul 2010 | A1 |
20100204648 | Stout et al. | Aug 2010 | A1 |
20100292656 | Groskopf | Nov 2010 | A1 |
20100292673 | Korogi et al. | Nov 2010 | A1 |
20110150958 | Davis et al. | Jun 2011 | A1 |
20110265825 | Rogers | Nov 2011 | A1 |
20110290799 | Anderson et al. | Dec 2011 | A1 |
20120016318 | Hoang et al. | Jan 2012 | A1 |
20120039765 | Solomon et al. | Feb 2012 | A1 |
20120216360 | Rogers et al. | Aug 2012 | A1 |
20120283693 | Anderson et al. | Nov 2012 | A1 |
20120302997 | Gardner | Nov 2012 | A1 |
20130331799 | Dasbach | Dec 2013 | A1 |
20150231384 | Ma | Aug 2015 | A1 |
20150374931 | Sugiki | Dec 2015 | A1 |
20160184558 | Raulerson | Jun 2016 | A1 |
Number | Date | Country |
---|---|---|
1649890 | Apr 2006 | EP |
2606930 | Jun 2013 | EP |
S58-501359 | Aug 1983 | JP |
2001-258713 | Sep 2001 | JP |
2002503968 | Feb 2002 | JP |
2009-511181 | Mar 2009 | JP |
2010-516324 | May 2010 | JP |
5867703 | Feb 2016 | JP |
8700441 | Jan 1987 | WO |
9929173 | Jun 1999 | WO |
2006019782 | Feb 2006 | WO |
2007044760 | Apr 2007 | WO |
2007137056 | Nov 2007 | WO |
2008100950 | Aug 2008 | WO |
2008157092 | Dec 2008 | WO |
2009136957 | Nov 2009 | WO |
2010039171 | Apr 2010 | WO |
2010143693 | Dec 2010 | WO |
2011053924 | May 2011 | WO |
2011066586 | Jun 2011 | WO |
Entry |
---|
Corrected Petition for Inter Partes Review Under 35 U.S.C. .sctn..sctn. 311-319 and 37 C.F.R. .sctn. 42,100 et seq., USPTO, Patent Trial and Appeal Board, Excelsior Medical Corporation v. Becton, Dickinson and Company, Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-48, Jun. 23, 2014. |
Decision, Institution of Inter Partes Review, 37 C.F.R..sctn. 42,108, USPTO, Patent Trial and Appeal Board, Excelsior Vledical Corporation v. Becton, Dickinson and Company, Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-21, Nov. 25, 2014. |
Patent Owner's Preliminary Response Under 37 C.F.R. .sctn. 42,10, USPTO, Patent Trial and Appeal Board, Excelsio Vledical Corporation v. Becton, Dickinson and Company, Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-30, Sep. 16, 2014. |
Number | Date | Country | |
---|---|---|---|
20190001115 A1 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15674389 | Aug 2017 | US |
Child | 16109376 | US | |
Parent | 15041931 | Feb 2016 | US |
Child | 15674389 | US | |
Parent | 14185827 | Feb 2014 | US |
Child | 15041931 | US |